Colorado is currently home to 1924 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
NCT04962139
Recruiting
The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2022
Locations: Oneness Investigational Site, Colorado Springs, Colorado
Conditions: Chronic Diabetic Foot Ulcers
Register for Updates
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
NCT04976595
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Lynn Institute of the Rockies, Colorado Springs, Colorado
Conditions: Hypogonadism
Register for Updates
Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins
NCT04474392
Recruiting
The study is designed to learn more about the causes of rheumatoid arthritis (RA). People who get RA have elevated protein markers called autoantibodies in their blood years before initial symptoms of arthritis. The goal of this study is to learn more about how autoantibodies in RA might be related to inflammation in the lungs.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/13/2022
Locations: University of Colorado Denver (Anschutz Medical Campus), Aurora, Colorado
Conditions: Rheumatoid Arthritis
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT02498951
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: University of Colorado, Denver, Colorado
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Register for Updates
Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients
NCT05264545
Recruiting
A 510k approved dental device for subjects requiring single or multiple tooth replacement with implants where immediate restoration/loading is preferred.
Gender:
All
Ages:
25 years and above
Trial Updated:
05/25/2022
Locations: McClain and Schallhorn Periodontics and Implant Dentistry, Aurora, Colorado
Conditions: Partially Edentulous Maxilla or Mandible
Register for Updates
Guiding Good Choices for Health
NCT04040153
Recruiting
This study evaluates the feasibility and effectiveness of implementing Guiding Good Choices (GGC), an anticipatory guidance curriculum for parents of early adolescents, in three large, integrated healthcare systems. By "parents," the study team is referring here and throughout this protocol to those adults who are the primary caregivers of children, irrespective of their biological relationship to the child. In prior community trials, GGC has been shown to prevent adolescent substance use (alcoh... Read More
Gender:
All
Ages:
Between 11 years and 12 years
Trial Updated:
05/19/2022
Locations: Kaiser Permanente Colorado, Aurora, Colorado
Conditions: Adolescent Substance Use
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Rocky Mountain Movement Disorders Center, Englewood, Colorado
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Recruiting
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2022
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
NCT04209543
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Downtown Women's Health Care, Denver, Colorado
Conditions: Vasomotor Symptoms, Menopausal Symptoms
Register for Updates
Decreasing Parental Stress of Caregivers of Infants With Infantile Spasms by Using Telemedicine Technology
NCT04086992
Recruiting
This study plans to learn more about how the use of new telemedicine technology can help with parental stress, costs, and overall satisfaction in care. Investigators are studying this in families who have children with a specific seizure type called infantile spasms and being treated with a medication called ACTH (adrenocorticotropic hormone). Infantile spasms is a rare epileptic encephalopathy that occurs within the first two years of life. It is associated with complicated and expensive treatm... Read More
Gender:
All
Ages:
Between 31 days and 30 months
Trial Updated:
05/02/2022
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Infantile Spasms, Non-Intractable
Register for Updates
Bright Light Exposure in Critical Ill Patients
NCT03822949
Recruiting
Elucidate the influence of intense light therapy pretreatment in patients undergoing cardiac surgery. We hypothesize that intense light exposure is associated with the peripheral stabilization of Per2 in human buccal swabs and plasma samples before surgery and with a decrease of Troponin I levels after surgery. In addition, we hypothesize that light therapy leads to Per2 dependent metabolic optimization in the human cardiac tissue. Therefore, a small piece of human heart tissue from the right at... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/02/2022
Locations: University of Colorado Denver | Anschutz Medical Campus, Denver, Colorado
Conditions: Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
Register for Updates
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
NCT03385486
Recruiting
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2022
Locations: University of Colorado Cancer Center, Denver, Colorado
Conditions: Stage III Melanoma, Stage IV Melanoma
Register for Updates